Companies › Amicus Therapeutics
3 active drug programs in 6 registered trials: 6 Phase 3; Metabolic and endocrine, Genitourinary; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Migalastat Alpha-galactosidase A stabiliser | GLA | Phase 3 | Fabry Disease | Dec 2026 |
| Cipaglucosidase Alfa (ATB200) Acid alpha-glucosidase (GAA) enzyme replacement therapy | GAA | Phase 3 | Pompe Disease (Late-onset); Glycogen Storage Disease Type II Infantile Onset | Mar 2027 |
| Miglustat (AT2221) Ceramide glucosyltransferase inhibitor | UGCG | Phase 3 | Pompe Disease (Late-onset); Glycogen Storage Disease Type II Infantile Onset | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04020055 | Migalastat | Phase 3 | Fabry Disease | Genitourinary | Dec 2026 |
| NCT03911505 | Cipaglucosidase Alfa (ATB200) | Phase 3 | Pompe Disease (Late-onset) | Metabolic and endocrine | Mar 2027 |
| NCT03911505 | Miglustat (AT2221) | Phase 3 | Pompe Disease (Late-onset) | Metabolic and endocrine | Mar 2027 |
| NCT04808505 | Cipaglucosidase Alfa (ATB200) | Phase 3 | Glycogen Storage Disease Type II Infantile Onset | Metabolic and endocrine | Jul 2027 |
| NCT04808505 | Miglustat (AT2221) | Phase 3 | Glycogen Storage Disease Type II Infantile Onset | Metabolic and endocrine | Jul 2027 |
| NCT06904261 | Migalastat | Phase 3 | Fabry Disease | Metabolic and endocrine | Dec 2027 |
Sanofi Astellas GeneCradle Spark Therapeutics AskBio Azafaros Idorsia Pharmaceuticals UniQure Biopharma Chiesi Farmaceutici Takeda
Beijing Dongfang Biotech Azafaros The United Bio-Technology (Hengqin) Actimed Therapeutics Fresenius Kabi
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.